Skip to main content

Advertisement

SpringerLink
Log in

A brief review of Japanese guidelines for the clinical use of 18F-FDG-PET/MRI 2012 (Ver 1.0)

  • Invited review article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

This is a brief review of Japanese FDG-PET/MRI guidelines for indications, procedures, cautions for the interpretation of images, and safety management, which were created by a joint task force of the Japanese Radiologic Society, Japanese Society of Nuclear Medicine, and Japanese Society of Magnetic Resonance Imaging. The guidelines aim at the appropriate and effective use of the newly developed PET/MRI modality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol. 2008;18:1077–86.

    Article  PubMed  Google Scholar 

  2. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198–205.

    Article  PubMed  Google Scholar 

  3. Boss A, Stegger L, Bisdas S, Kolb A, Schwenzer N, Pfister M, et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol. 2011;21:1439–46.

    Article  PubMed  Google Scholar 

  4. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53:546–51.

    Article  PubMed  CAS  Google Scholar 

  5. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928–38.

    Article  PubMed  Google Scholar 

  6. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, Part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244–52.

    Article  PubMed  Google Scholar 

  7. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med. 1999;40:737–46.

    PubMed  CAS  Google Scholar 

  8. Kim YK, Lee DS, Lee SK, Chung CK, Chung JK, Lee MC. 18F-FDG PET in localization of frontal lobe epilepsy: comparison of visual and SPM analysis. J Nucl Med. 2002;43:1167–74.

    PubMed  Google Scholar 

  9. Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry. 1993;56:615–21.

    Article  PubMed  CAS  Google Scholar 

  10. Sasaki M, Kuwabara Y, Yoshida T, Fukumura T, Morioka T, Nishio S, et al. Carbon-11-methionine PET in focal cortical dysplasia: a comparison with fluorine-18-FDG PET and technetium-99 m-ECD SPECT. J Nucl Med. 1998;39:974–7.

    PubMed  CAS  Google Scholar 

  11. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med. 2002;29:1257–66.

    Article  Google Scholar 

  12. Schelbert HR. 18F-deoxyglucose and the assessment of myocardial viability. Semin Nucl Med. 2002;32:60–9.

    Article  PubMed  Google Scholar 

  13. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.

    PubMed  Google Scholar 

  14. Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography—an autopsy case. Circulation. 2010;122:535–6.

    Article  PubMed  Google Scholar 

  15. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.

    Article  PubMed  Google Scholar 

  16. Guidelines for clinical use of FDG PET, PET/CT 2012. Jpn J Nucl Med (Kaku Igaku). 2012;49:391–401. http://www.jsnm.org/guideline/20100330.

  17. Guidelines for clinical use of FDG PET, PET/CT 2010. Jpn J Nucl Med (Kaku Igaku). 2010;47:153–62

    Google Scholar 

  18. Guidelines for PET Examination Using In-house-produced FDG (2nd Edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–22. http://www.jsnm.org/files/pdf/guideline/fdg_guide2-2.pdf.

  19. Hofmann M, Steinke F, Scheel V, Charpiat G, Farquhar J, Aschoff P, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875–83.

    Article  PubMed  Google Scholar 

  20. Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812–8.

    Article  PubMed  Google Scholar 

  21. Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333–6.

    Article  PubMed  Google Scholar 

  22. Malone IB, Ansorge RE, Williams GB, Nestor PJ, Carpenter TA, Fryer TD. Attenuation correction methods suitable for brain imaging with a PET/MRI scanner: a comparison of tissue atlas and template attenuation map approaches. J Nucl Med. 2011;52:1142–9.

    Article  PubMed  Google Scholar 

  23. CMR image acquisition protocols version 1.0: 2007. http://scmr.jp/mri/pdf/scmr_protocols_2007_jp.pdf.

  24. Morita N, Harada M, Otsuka H, Melhem ER, Nishitani H. Clinical application of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci. 2010;9:167–75.

    Article  PubMed  CAS  Google Scholar 

  25. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR. 1995;16:1593–603.

    PubMed  CAS  Google Scholar 

  26. Gerstner ER, Sorensen AG. Diffusion and diffusion tensor imaging in brain cancer. Semin Radiat Oncol. 2011;21:141–6.

    Article  PubMed  Google Scholar 

  27. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31:538–48.

    Article  PubMed  Google Scholar 

  28. Romano A, Rossi Espagnet MC, Calabria LF, Coppola V, Figà Talamanca L, Cipriani V, et al. Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours. Radiol Med. 2012;117:445–60.

    Article  PubMed  CAS  Google Scholar 

  29. Hayashi S, Ito K, Shimada M, Tsubuku M, Kaneko I, Kogure T, et al. Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma. Radiat Med. 1995;13:167–70.

    PubMed  CAS  Google Scholar 

  30. Guidelines for PET Examination Using In-house-produced FDG (2nd Edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–22.

  31. Guidelines for Safety Security in FDG-PET Examination (2005). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–26.

    Google Scholar 

  32. Guidelines for Imaging Techniques in FDG-PET Examination. Jpn J Nucl Med Technol (Kaku Igaku Gijutsu) 2007;27:425–56.

    Google Scholar 

  33. Guidance for industry and FDA staff—Criteria for significant risk investigations of magnetic resonance diagnostic devices: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. July 14, 2003.

  34. Shellock FG. The reference manual for magnetic resonance safety, implants and devices: 2008 eds. Biomedical Research Publishing Group, Los Angeles.

Download references

Acknowledgments

No potential conflicts of interest were disclosed. The author thanks Drs. Ukihide Tateishi, Yuji Nakamoto, Koji Murakami, Akira Toriihara, Munenobu Nogami, Tadaki Nakahara, Kazunori Kubota, Mitsuaki Tatsumi, Mototaka Miyake, Yumiko Tanaka, and Seiji Kurata, who developed the Japanese Guidelines for the Clinical Use of 18F-FDG-PET/MRI 2012 (Ver 1.0). This work was supported by Japanese Radiologic Society, Japanese Society of Nuclear Medicine, Japanese Society of Magnetic Resonance in Medicine, Insurance Committee of Japanese Radiologic Society, PET MRI Insurance Committee of Japanese Radiologic Society, and Health Insurance Committee of Japanese Society of Nuclear Medicine. This work was also supported in part by Grand-in-Aid for Research Foundation for Community Medicine, Japan. The author also thanks to SIEMENS Healthcare Japan K.K., GE Healthcare Japan Corporation, and Philips Electronics Japan, Ltd. for support and data handling.

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Tohoku University, 1-1 Seiryomachi, Aobaku, Sendai, 980-8574, Japan

    Tomohiro Kaneta

Authors
  1. Tomohiro Kaneta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomohiro Kaneta.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 854 kb)

Supplementary material 2 (PDF 380 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaneta, T. A brief review of Japanese guidelines for the clinical use of 18F-FDG-PET/MRI 2012 (Ver 1.0). Ann Nucl Med 27, 309–313 (2013). https://doi.org/10.1007/s12149-013-0710-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-013-0710-z

Keywords

Search

Navigation